ADAGENE INC
NASDAQ: ADAG (Adagene Inc.)
Kemas kini terakhir: 9 jam lalu2.85
-0.08 (-2.73%)
| Penutupan Terdahulu | 2.93 |
| Jumlah Dagangan | 297,964 |
| Harga / Jualan (P/S) | 16.50 |
| Harga / Buku (P/B) | 2.21 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -17,082.39% |
| EPS Cair (TTM) | -0.740 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -87.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 36.60% |
| Nisbah Semasa (MRQ) | 2.30 |
| Aliran Tunai Operasi (OCF TTM) | -29.70 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -18.87 M |
| Pulangan Atas Aset (ROA TTM) | -21.92% |
| Pulangan Atas Ekuiti (ROE TTM) | -55.21% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Adagene Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | 3.0 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.13 |
|
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 4.70% |
| % Dimiliki oleh Institusi | 33.39% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Moneta Group Investment Advisors Llc | 30 Jun 2026 | 200,000 |
| Mill Creek Capital Advisors, Llc | 31 Mar 2026 | 199,610 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| TAM MAN KIN | 2.97 | - | 2,000 | 5,940 |
| Jumlah Keseluruhan Kuantiti Bersih | 2,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 5,940 | |||
| Purata Pembelian Keseluruhan ($) | 2.97 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| TAM MAN KIN | Pegawai | 23 Sep 2026 | Beli (+) | 2,000 | 2.97 | 5,940 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |